Figure 3From: Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patientsSurvival curves among the three intrinsic subtypes. a) The median progression-free survival time of mrTNBC patients was 7.5Â months, while that of luminal/HER2-negative patients was 12.2Â months, and that of HER2-positive patients was 4.5Â months. b) The median overall survival time of mrTNBC patients was 11.1Â months, while that of luminal/HER2-negative patients was 26.5Â months, and that of HER2-positive patients was 14.9Â months. HER2, human epidermal growth factor receptor 2; mrTNBC, metastatic recurrent triple negative breast cancer.Back to article page